Author Archives: Lu Rahman

#Antibody #Cancer #Immuno-oncology #Immunotherapy

Twist Biopharma: antibody candidates against GPCR therapeutic targets

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built… Read More

#Exclusive Content #News

#Drug safety #Drug toxicity #Preclinical development

How to enhance the predictability of preclinical development: webinar

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human… Read More

#Editor's Choice #News

Enhancing the predictability of preclinical development

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human… Read More

Webinar date:
Brought to you by PerkinElmer
#Webinars

#Drug discovery #Immuno-oncology #Immunotherapy #Webinar

Are you involved in immuno-oncology or cancer immunotherapy research?

This webinar, Evaluation of checkpoint inhibitor therapies using an MLR assay, is hosted by DDW and supported by Sartorius and will provide useful information for immuno-oncology research and the cancer immunotherapy drug discovery process. The event took place on 12 May. Watch for free here. In the field of immunotherapy… Read More

#Editor's Choice #News

#Antibodies #Assays #Pharmaceuticals #Small molecules

Synthesising new solutions for small molecule antibodies

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals… Read More

#Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Drug discovery

Why collaboration matters and how to make it a success

Drug discovery is complex and the expertise it requires is vast. Matthew A. Clark, Chief Executive Officer, X-Chem, talks to Lu Rahman about the company’s experience of collaboration and how it enables innovation, flexibility and problem-solving. Drug discovery is the most interdisciplinary of all scientific endeavours, says Clark. “To successfully… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#Antibodies #Covid-19 #Drug development #Drug discovery #Therapies #Vaccines

Covid-19 response speed sets a new standard in drug discovery

    This paid-for advertorial by Berkeley Lights appeared in DDW Volume 22, Issue 2 – Spring 2021 The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Several therapeutic antibodies and vaccine… Read More

#Covid-19 #Exclusive Content

#CRISPR #Gene editing #Genetic modification #Mouse models

With so many technologies for genetically modifying models, it pays to choose wisely

Listen to this article on the DDW Podcast: By Caroline Horizny, Taconic Biosciences When a pharmaceutical company, biotech firm, or academic institution embarks on a preclinical research project, one of the most critical early-stage decisions is which animal model will best support the project’s objective. Mouse models remain a go-to resource… Read More

#Exclusive Content

#Cell painting #Drug discovery #High Content Screening

Cell painting: a vibrant future for phenotypic drug discovery

The cell painting approach evokes new ideas and strategies for high-content screening (HCS) practitioners to identify new drugs and to study mechanisms of action by leveraging machine learning to measure subtle phenotypic changes at the cellular level. Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content… Read More

#Exclusive Content

#Antibodies #Immune system #Vaccine candidate #Vaccines

How a soccer ball and a computer inform new vaccines

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone

#AI / data analytics / healthtech / informatics #Diabetes #Drug development #Precision medicine

The power of precision medicine

Listen to this article on the DDW Podcast: Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we  treat disease. We hear increasingly about the shift away from one size fits all medicine. It does of course, make perfect sense and… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

Systems-level analyses reveal that children with the COVID-associated inflammatory syndrome, MIS-C, display a unique immunological profile

Olink has created a summary article of a study recently published by Consiglio et al. in Cell. This study focuses on the rare cases when children develop Multisystem Inflammatory Syndrome in Children (MIS-C) in response to infection by the SARS-CoV-2 virus. Typically in these cases the syndrome manifests four to… Read More

#Intelligence #Resources

#Biomedical research #Drug discovery #iPSC #Synthetic biology

Sitting down with…bit.bio

bit.bio is a synthetic biology company working on producing every human cell type at scale, with the aim of transforming the research and medicine landscape. Farah Patell-Socha, PhD, VP Research Products tells Lu Rahman about some of the company’s groundbreaking work in this field and the benefits it is creating… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug development #Drug discovery #Generics #Pharmaceuticals

Drug discovery and India: the future looks bright

As the world’s largest generic producer how far advanced is India’s drug discovery push and where does it stand on the global stage? Lu Rahman explores. India has become a key player in the global pharmaceutical sector. The value of its part in this industry is expected to reach $120… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Intelligence #Market Reports #News